Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes" (TOLEDDO)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05305794 |
Recruitment Status :
Active, not recruiting
First Posted : March 31, 2022
Last Update Posted : May 3, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Between 16% and 22% of type 1 diabetic patients present a clinical and biological profile of insulin resistance favored by a family history of type 2 diabetes or metabolic syndrome. They constitute a group of patients with "double diabetes" since they have both true type 1 diabetes and inherited insulin resistance, typical of type 2 diabetes.
For several years, GLP1 agonists have been successfully used in the treatment of type 2 diabetes, leading to very significant improvements in glycemic control and weight loss.
Because of the insulin-sensitizing power of GLP1 agonists, the investigators hypothesize that they could reduce insulin resistance in patients with "double diabetes" and thus improve their glycemic control.
The investigators propose to use in this study semaglutide, the most recent and most potent GLP1 agonist (superiority demonstrated compared to exenatide LP and dulaglutide) and administered as a weekly subcutaneous injection (in contrast to liraglutide administered daily).
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Double Diabetes | Drug: Insulin + semaglutide treatment Drug: Usual insulin treatment Biological: Biological check-up | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 76 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes": a Randomized Open-label Study |
Actual Study Start Date : | July 12, 2022 |
Estimated Primary Completion Date : | August 2026 |
Estimated Study Completion Date : | August 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Semaglutide |
Drug: Insulin + semaglutide treatment
Usual insulin treatment + semaglutide (0.25 mg/week for 4 weeks, then 0.50 mg/week for 4 weeks, then 1 mg/week for 18 weeks, i.e. a total duration of 26 weeks). Upon introduction of semaglutide (ozempic) treatment, insulin doses will be reduced by 10% (basal insulin, basal rate and bolus) Biological: Biological check-up at D0, D90 and D180 |
Active Comparator: Control |
Drug: Usual insulin treatment
Usual insulin treatment Biological: Biological check-up at D0, D90 and D180 |
- Percentage of time spent within glycemic target range (0.70-1.80 g/l) [ Time Frame: Change from baseline at Day 180 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Person who has given written consent
- Patient over 18 years of age
- Patient with type 1 diabetes confirmed by a C-peptide below laboratory standards
- Age at diagnosis < 35 years
- Treated with optimized insulin therapy (multi-injections or pump) for at least 1 year, having received specific therapeutic education on insulin dose adaptation.
- BMI (weight/height2) ≥ 27 Kg/m².
-
At least one of the following criteria:
- Family history of type 2 diabetes (parents, grandparents, uncles, aunts, brothers and sisters)
- Family history of obesity (BMI>30 Kg/m2) (parents, grandparents, uncles, aunts, siblings)
- Triglycerides > 1.50g/l (1.7mmol/l)
- HDL< 0.5 g/l (1.29 mmol/l) in women, HDL<0.4 g/l (1.03 mmol/l) in men
- HbA1c ≥ 7.5% and < 12% in the 3 months preceding inclusion
- Having continuous glucose monitoring by a CGM (Holter Glucose Monitoring) system: Guardian, Dexcom or Free Style Libre
- For women of childbearing age: using an effective method of contraception until 2 months after the end of treatment. Effective contraception includes: hormonal contraception, intrauterine device, bilateral tubal occlusion, vasectomy and sexual abstinence
Exclusion Criteria:
- person not affiliated to national health insurance
- Pregnant, parturient or breastfeeding woman
- HbA1c ≥12% in the 3 months preceding inclusion.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy, confirmed by a fundus examination performed in the 6 months preceding the selection
- Person under a measure of legal protection (curatorship, guardianship)
- Renal insufficiency (GFR<30 ml/mn)
- Hepatic insufficiency (INR> 1.5)
- BMI >40 kg/m².
- History of bariatric surgery
- History of pancreatitis
- Allergy to the active substance or to one of the excipients of OZEMPIC®.
- Patients treated with GLP1 agonists or oral antidiabetics in the month preceding month prior to inclusion
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05305794
France | |
Chu Dijon Bourgogne | |
Dijon, France, 21000 |
Responsible Party: | Centre Hospitalier Universitaire Dijon |
ClinicalTrials.gov Identifier: | NCT05305794 |
Other Study ID Numbers: |
BOUILLET PHRCI 2020 |
First Posted: | March 31, 2022 Key Record Dates |
Last Update Posted: | May 3, 2024 |
Last Verified: | May 2024 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Insulin |
Insulin, Globin Zinc Semaglutide Hypoglycemic Agents Physiological Effects of Drugs Glucagon-Like Peptide-1 Receptor Agonists |